

## **Gemina Announces Closing of \$910,000 Convertible Note Financing**

***This news release is intended for distribution only in Canada and is not intended for distribution to US newswire services, or for release, publication, or distribution in whole or in part, in or in the United States or in the United States.***

**March 18, 2024, Vancouver, British Columbia: Gemina Laboratories Ltd.** (CSE: GLAB) (FRA:8I7) (the “**Company**” or “**Gemina**”) is pleased to announce that further to its news release dated February 22, 2024, it has raised gross proceeds of \$910,000 under its non-brokered private placement (the “**Private Placement**”) of unsecured convertible notes of the Company (the “**Notes**”). Please see the Company’s news release dated February 22, 2024 for additional details regarding the terms of the Notes.

The proceeds from the Private Placement are intended to be used for general working capital and corporate purposes. All securities issued pursuant to the Private Placement are and will be subject to a four month hold period from the date of issue, expiring July 19, 2024, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.

No finder's fees, commission, bonus, agent's option or other compensation was paid in connection with the Private Placement.

None of the securities sold under the Private Placement have been and will not be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

On Behalf of the Board of Directors

Brian Firth  
Chief Executive Officer  
Gemina Laboratories Ltd.

### **About Gemina Laboratories Ltd.**

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at [www.geminalabs.com](http://www.geminalabs.com).

***Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.***

## **Forward-Looking Information**

*This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the anticipated use of proceeds raised under the Private Placement.*

*In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that the Company will use the proceeds of the Private Placement as currently anticipated.*

*The forward-looking statements in this news release involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: market uncertainty and the inability of the Company to use the proceeds raised under the Private Placement for the purposes anticipated.*

*Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.*